Acta Neuropathologica Communications (Nov 2023)

Variant allelic frequencies of driver mutations can identify gliomas with potentially false-negative MGMT promoter methylation results

  • Matthew McCord,
  • Pouya Jamshidi,
  • Vineeth Thirunavu,
  • Lucas Santana-Santos,
  • Erica Vormittag-Nocito,
  • David Dittman,
  • Stephanie Parker,
  • Joseph Baczkowski,
  • Lawrence Jennings,
  • Jordain Walshon,
  • Kathleen McCortney,
  • Kristyn Galbraith,
  • Hui Zhang,
  • Rimas V. Lukas,
  • Roger Stupp,
  • Karan Dixit,
  • Priya Kumthekar,
  • Amy B. Heimberger,
  • Matija Snuderl,
  • Craig Horbinski

DOI
https://doi.org/10.1186/s40478-023-01680-0
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 15

Abstract

Read online

Abstract MGMT promoter methylation testing is required for prognosis and predicting temozolomide response in gliomas. Accurate results depend on sufficient tumor cellularity, but histologic estimates of cellularity are subjective. We sought to determine whether driver mutation variant allelic frequency (VAF) could serve as a more objective metric for cellularity and identify possible false-negative MGMT samples. Among 691 adult-type diffuse gliomas, MGMT promoter methylation was assessed by pyrosequencing (N = 445) or DNA methylation array (N = 246); VAFs of TERT and IDH driver mutations were assessed by next generation sequencing. MGMT results were analyzed in relation to VAF. By pyrosequencing, 56% of all gliomas with driver mutation VAF ≥ 0.325 had MGMT promoter methylation, versus only 37% with VAF < 0.325 (p < 0.0001). The mean MGMT promoter pyrosequencing score was 19.3% for samples with VAF VAF ≥ 0.325, versus 12.7% for samples with VAF < 0.325 (p < 0.0001). Optimal VAF cutoffs differed among glioma subtypes (IDH wildtype glioblastoma: 0.12–0.18, IDH mutant astrocytoma: ~0.33, IDH mutant and 1p/19q co-deleted oligodendroglioma: 0.3–0.4). Methylation array was more sensitive for MGMT promoter methylation at lower VAFs than pyrosequencing. Microscopic examination tended to overestimate tumor cellularity when VAF was low. Re-testing low-VAF cases with methylation array and droplet digital PCR (ddPCR) confirmed that a subset of them had originally been false-negative. We conclude that driver mutation VAF is a useful quality assurance metric when evaluating MGMT promoter methylation tests, as it can help identify possible false-negative cases.

Keywords